X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
DIVI'S LABORATORIES LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

DIVI'S LABORATORIES LIMITED  (DIVI)


Here is the latest financial fact sheet of Divis Laboratories. For more details, see the Divis Laboratories quarterly results and Divis Laboratories share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
divis laboratories - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 623.1       No. of shares m 265.47
    Mkt Cap Rs m 165,413       % ch % 0.0
    Vol '000 297.7       % ch week % -18.4
    P/E X 14.8       % ch 1-mth % -18.9
    P/CF X 13.4       % ch 12-mth % -35.9
    EPS (TTM) Rs 42.0       52 week H/L Rs 1,380.0/611.6
(As on Mar 24, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs8431,2331,4591,8812,484 
Low Rs6687529051,217918 
Sales per share (Unadj.) Rs140.4161.6190.8234.7142.3 
Earnings per share (Unadj.) Rs40.245.458.364.241.9 
Diluted earnings per shareRs20.122.729.132.141.9 
Cash flow per share (Unadj.) Rs44.951.265.274.446.3 
Dividends per share (Unadj.) Rs13.0015.0020.0020.0010.00 
Adj. dividends per shareRs6.507.5010.0010.0010.00 
Dividend yield (eoy) %1.71.51.71.30.6 
Book value per share (Unadj.) Rs160.6188.4223.3263.3161.5 
Adj. book value per shareRs80.394.2111.6131.7161.5 
Shares outstanding (eoy) m132.73132.73132.73132.73265.47 
Bonus/Rights/Conversions  ESOP---- 
Price / Sales ratio x5.46.16.26.612.0 
Avg P/E ratio x18.821.920.324.140.6 
P/CF ratio (eoy) x16.819.418.120.836.7 
Price / Book Value ratio x4.75.35.35.910.5 
Dividend payout %32.433.134.331.223.9 
Avg Mkt Cap Rs m100,278131,735156,887205,599451,525 
No. of employees `000NANANANA3.7 
Total wages/salary Rs m1,5091,9772,3252,9043,649 
Avg. sales/employee Rs ThNMNMNMNM10,184.4 
Avg. wages/employee Rs ThNMNMNMNM984.1 
Avg. net profit/employee Rs ThNMNMNMNM2,998.5 
  INCOME DATA
Net Sales Rs m18,63921,44825,32131,14937,764 
Other income Rs m561448706447848 
Total revenues Rs m19,19921,89726,02731,59638,612 
Gross profit Rs m6,9048,15210,14511,65214,138 
Depreciation Rs m6217709211,3601,182 
Interest Rs m3718211923 
Profit before tax Rs m6,8067,8129,90910,72113,781 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,4741,7922,1762,2062,662 
Profit after tax Rs m5,3336,0207,7338,51511,119 
Gross profit margin %37.038.040.137.437.4 
Effective tax rate %21.722.922.020.619.3 
Net profit margin %28.628.130.527.329.4 
  BALANCE SHEET DATA
Current assets Rs m17,51018,64122,56427,72430,947 
Current liabilities Rs m5,5385,5456,2747,7555,195 
Net working cap to sales %64.261.164.364.168.2 
Current ratio x3.23.43.63.66.0 
Inventory Days Days133142134136117 
Debtors Days Days97871048785 
Net fixed assets Rs m9,20412,12113,66315,27117,027 
Share capital Rs m266266266266531 
"Free" reserves Rs m21,04524,73529,36334,68342,341 
Net worth Rs m21,31525,00629,63434,95442,877 
Long term debt Rs m262116115 
Total assets Rs m27,56731,38837,10544,11449,684 
Interest coverage x183.0439.9482.0577.4595.0 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.70.70.70.8 
Return on assets %19.519.220.919.322.4 
Return on equity %25.024.126.124.425.9 
Return on capital %32.131.333.530.732.2 
Exports to sales %86.286.789.284.385.3 
Imports to sales %19.521.820.023.922.9 
Exports (fob) Rs m16,06918,60222,57526,24432,198 
Imports (cif) Rs m3,6384,6815,0697,4428,654 
Fx inflow Rs m16,15118,78922,61726,31732,270 
Fx outflow Rs m3,7194,7965,1837,5888,775 
Net fx Rs m12,43213,99317,43418,72923,496 
  CASH FLOW
From Operations Rs m 3,384 4,800 5,568 8,263 10,379 
From Investments Rs m -2,044 -2,545 -3,052 -5,208 -4,135 
From Financial Activity Rs m -1,311 -2,308 -2,485 -3,030 -6,241 
Net Cashflow Rs m 28 -53 31 25 3 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for divi's laboratories limited

 Share Holding
Indian Promoters : 52.0%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 11.8%
FIIs : 19.0%
ADR/GDR : 0.0%
Free float : 17.2%
Shareholders : 31,796
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: 7-1-77/E/1/303, Divi Towers, Dharam Karan Road, Ameerpet, Hyderabad-16
    E-MAIL: cs@divislaboratories.com     WEB: www.divislaboratories.com
    TELEPHONE: (040) 2378 6300     FAX: (040) 2378 6460
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
    AUDITOR: P. V. R. K. Nageswara Rao & Co.
CHM: Murali K. Divi (MD) COMP SEC: P. V. Lakshmi Rajani YEAR OF INC: 1990 BSE CODE: 532488 FV (Rs): 2 DIV YIELD (%): 1.6

More pharmaceuticals Company Fact Sheets:   SUVEN LIFESANOFI INDIALUPIN LTDVENUS REMEDIESPLETHICO PHARMA


Today's Market

Global Financial Markets Remain Cautious(RoundUp)

Most of the global financial markets ended the week on a negative note. Major global markets were cautious over the week over concerns of the Trump administration's ability to push out reforms.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why Mutual Fund Investors Should Not Worry About Market High. But...(Outside View)

Mar 22, 2017

PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.

More

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - WOCKHARDT LTD. COMPARISON

Compare Company With Charts

COMPARE DIVIS LABORATORIES WITH

MARKET STATS